Fed Circ. Sets Product-By-Process Patent Restrictions
In two cases over a patent related to Abbott Laboratories' bacterial infection drug Omnicef, an appeals court has ruled that defining a product in a patent by the process through which...To view the full article, register now.
Already a subscriber? Click here to view full article